Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

41.57
+0.77001.89%
Volume:232.51K
Turnover:9.64M
Market Cap:1.42B
PE:-6.43
High:42.38
Open:40.38
Low:40.38
Close:40.80
52wk High:109.00
52wk Low:33.40
Shares:34.14M
Float Shares:33.55M
Volume Ratio:0.73
T/O Rate:0.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:1.57
PE(LYR):-4.27

Loading ...

Nektar Says Phase 2b Rezolve-AA Trial Posts New 6-Month Off-Treatment Rezpegaldesleukin Data in Severe Alopecia Areata

Reuters
·
Sep 28

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (Eadv) Congress 2026

THOMSON REUTERS
·
Sep 28

Canaccord Genuity Sticks to Their Buy Rating for Nektar Therapeutics (NKTR)

TIPRANKS
·
Sep 28

Nektar Therapeutics Price Target Maintained with a $178.00/Share by BTIG

Dow Jones
·
Sep 28

Nektar awarded $90M in Eli Lilly breach of contract case

TIPRANKS
·
Sep 28

Nektar selloff on trial brings ‘strong entry point,’ says BTIG

TIPRANKS
·
Sep 28

Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 26

U.S. Stocks on the MOVEx-Microsoft, Nike, Nektar Therapeutics

Reuters
·
Sep 26

Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case

MT Newswires Live
·
Sep 26

Nektar Therapeutics Price Target Maintained with a $178.00/Share by BTIG

Dow Jones
·
Sep 25

Sector Update: Healthcare Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Sep 25

Jury Finds Lilly Breaches Implied Covenant in Rezpegaldesleukin License, Awards Nektar USD 90 Million Plus Interest

Reuters
·
Sep 25

Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant of Good Faith in License Agreement - SEC Filing

THOMSON REUTERS
·
Sep 25

Nektar Therapeutics - Jury Awards Nektar Therapeutics $90 Mln in Damages Plus Interest - SEC Filing

THOMSON REUTERS
·
Sep 25

Nektar shares pressured by jury notes in Lilly case, says B. Riley

TIPRANKS
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nektar Therapeutics (NKTR)

TIPRANKS
·
Sep 23

Nektar Therapeutics is Maintained at Neutral by Wedbush

Dow Jones
·
Sep 23

Wedbush Cuts Price Target on Nektar Therapeutics to $50 From $80, Keeps Neutral Rating

MT Newswires Live
·
Sep 23

Nektar Therapeutics : Wedbush Cuts Target Price to $50 from $80

THOMSON REUTERS
·
Sep 23

Nektar Therapeutics Price Target Maintained with a $178.00/Share by BTIG

Dow Jones
·
Sep 16